Monoclonal antibodies directed against TNF-α (Inflixamab, Adalimumab, Etanercept) have been extremely effective in the treatment of RA and may target, in part, intermediate and non-classical CD16+ monocytes. Here, TNF is linked to rheumatoid arthritis.